Serum Free Light Chains as Markers of Progression in Chronic Kidney Disease
의약학 > 내과학
고은실 , 황현철 , 정성진 , 신석준 , 박철휘 , 장윤식
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 228(총1페이지)
42846607.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Introduction: In patients with chronic kidney disease (CKD), as the glomerular filtration rate (GFR) reduces, the renal clearance of free light chains (FLC) decreases and serum concentrations rise. The aim of this study was to investigate the potential of FLC as risk markers for development and progression of CKD. Methods: We assayed serum and urine samples from 318 patients with CKD of various causes. Patients with monoclonal gammopathy were excluded (n=40). Serum creatinine and 24 hr urine protein and albumin levels were measured and, estimated GFR (eGFR) was calculated using CKD-EPI method. Results: Compared with in control group (n=17), serum kappa and lambda FLC concentrations were more elevated in CKD group (n=261) (p<0.01). However, there was no significant difference in hs-CRP, LDH, age and sex between both groups. In the univariate regression analysis model, kappa and lambda FLC concentration in the serum and urine, age and LDH level were associated with eGFR. In the final multiple linear regression analysis model, only serum kappa and lambda FLC concentrations were inversely correlated with eGFR (β=-0.494, p<0.01 for kappa and β=-0.280, p=0.02 for lambda). Conclusion: Increased concentrations of serum kappa and lambda FLC were associated with decreased GFR. These data mean that serum kappa and lambda FLC concentrations are markers of progressive renal dysfunction in patients with CKD.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.